Skip to content
Screener

Repligen RGEN Operating Cash Flow

Operating Cash Flow at other companies

Thermo Fisher Scientific logo
Thermo Fisher ScientificTMO
$2.13B+51.9%
Danaher logo
DanaherDHR
$1.53B+14.6%
Maravai LifeSciences Holdings, Inc. logo
Maravai LifeSciences Holdings, Inc.MRVI
$8.67M+192%
Bio-Rad Laboratories logo
Bio-Rad LaboratoriesBIO
$108.1M-16.8%
Charles River Laboratories logo
Charles River LaboratoriesCRL
$179.73M-12.2%
TEC
Bio-TechneTECH
$86.66M+111%

Other financials

Income statement

See full
Revenue$204.1M+11.9%
Gross profit$110.0M+20.7%
Operating income$14.0M+0.6%
Net income$5.0M-66.3%
EPS (diluted)$0.09-65.4%

Balance sheet

See full
Cash & equivalents$606.8M-14.4%
Total debt$690.9M+354%
Total equity$2.1B+2.4%
Total assets$3.0B+1.7%

Cash flow

See full
CapEx$5.3M-24.9%
Free cash flow$27.4M+27.5%

Valuation

See full
Market cap$8.95B+42.1%
Enterprise value$9.03B+57.3%
P/E215.5×
P/S11.6×+0.3×

Profitability

See full
Gross margin47.6%+0.9pp
Operating margin15.6%-11.0pp
Net margin17.3%-3.5pp
FCF margin22%+6.9pp

Returns & leverage

See full
Return on equity2%+1.6pp
Debt / equity0.3×+0.3×
Current ratio9.1×+0.5×

Where this comes from

Reported directly by Repligen in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.

The source filing: Repligen’s 10-Q, filed July 29, 2026.

Filed
Jul 29, 2026, 4:19 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-323773
Line itemSix Months Ended June 30, 2026Six Months Ended June 30, 2025
Accrued liabilities(527)(2,995)
Operating lease liabilities(13,358)(9,804)
Noncurrent liabilities1,490256
Total cash provided by operating activities61,06143,614
Cash flows for investing activities
Acquisitions, net of cash acquired(69,954)
Divestiture proceeds, net of cash divested3,637
Purchases of marketable securities(130,698)

ITEM 1. Financial Statements

FAQ

What is Repligen's operating cash flow?
Repligen (RGEN) reported operating cash flow of $32.77M in Q2 2026.
How has Repligen's operating cash flow changed year-over-year?
Repligen's operating cash flow increased by 14.5% year-over-year, from $28.61M to $32.77M.
What is the long-term trend for Repligen's operating cash flow?
Over 4 years (2021 to 2025), Repligen's operating cash flow has grown at a -0.3% compound annual growth rate (CAGR), from $119.02M to $117.42M.
What does operating cash flow mean?
Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.

Ask your AI about Repligen's operating cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude